AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9663366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg/d (150 mg QD)
Number of subjects: 362
Study 9663366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/d (150 mg BID)
Number of subjects: 362
Study 9663366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 7829013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula 18 g/day
Number of subjects: 7
Study 7829013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3046791 — intervention group
Group type: EXPERIMENTAL
Intervention: darodipine 50 mg twice a day
Number of subjects: 43
Study 3046791 — intervention group
Group type: EXPERIMENTAL
Intervention: darodipine 100 mg twice a day
Number of subjects: 43
Study 3046791 — intervention group
Group type: EXPERIMENTAL
Intervention: darodipine 150 mg twice a day
Number of subjects: 43
Study 3046791 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study 29611518 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of oxaliplatin-containing chemotherapy
Number of subjects: 6088
Study 29611518 — intervention group
Group type: COMPARATOR
Intervention: 6 months of oxaliplatin-containing chemotherapy
Number of subjects: 6088
Study 27629438 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based Anger Management Training (12-week program)
Number of subjects: 85
Study 27629438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study 25843292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag-DC-CIK immunotherapy
Number of subjects: 0
Study 25843292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25843292 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK treatment
Number of subjects: 0
Study 25843292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag-DC-CIK treatment
Number of subjects: 0
Study 23627672 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactide-based temporary skin substitute
Number of subjects: 0
Study 23627672 — intervention group
Group type: COMPARATOR
Intervention: Autologous skin grafts
Number of subjects: 0
Study 21865087 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine (Cervarix, GlaxoSmithKline)
Number of subjects: 4210
Study 21865087 — intervention group
Group type: COMPARATOR
Intervention: Control hepatitis A vaccine (modified preparation of Havrix, GlaxoSmithKline)
Number of subjects: 4210
Study 19968681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 27
Study 19968681 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilatation (FMD)
Number of subjects: 27
Study 19968681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine alone or associated with placebo or L-arginine
Number of subjects: 27
Study 19968681 — intervention group
Group type: COMPARATOR
Intervention: L-arginine infusion
Number of subjects: 27
Study 19968681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16713455 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus narrowband UVB phototherapy
Number of subjects: 24
Study 16713455 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus narrowband UVB phototherapy
Number of subjects: 24
Study 15262119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal IL-2 therapy
Number of subjects: 17
Study 15262119 — intervention group
Group type: COMPARATOR
Intervention: Sera from nonresponders
Number of subjects: 17
Study 15262119 — intervention group
Group type: COMPARATOR
Intervention: Chromatographically fractionated sera from nonresponders
Number of subjects: 17
Study 11481400 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled low carotenoid diets
Number of subjects: 19
Study 9544599 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOU care
Number of subjects: 113
Study 9544599 — intervention group
Group type: COMPARATOR
Intervention: Hospital Inpatient care
Number of subjects: 113
Study 7511150 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (Group A)
Number of subjects: 109
Study 2899234 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 210
Study 2899234 — intervention group
Group type: EXPERIMENTAL
Intervention: dothiepin
Number of subjects: 210
Study 2899234 — intervention group
Group type: EXPERIMENTAL
Intervention: cognitive and behaviour therapy
Number of subjects: 210
Study 2899234 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐help treatment programme
Number of subjects: 210
Study 2899234 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 210
Study 31631314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid force
Number of subjects: 74
Study 31631314 — intervention group
Group type: COMPARATOR
Intervention: Paralaryngeal force
Number of subjects: 74
Study 31356896 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback intervention (EEG-contingent stimulation)
Number of subjects: 17
Study 31356896 — intervention group
Group type: COMPARATOR
Intervention: Sham-control (sensorimotor stimulations independent of EEG)
Number of subjects: 17
Study 29128736 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive practice conditions
Number of subjects: 40
Study 29128736 — intervention group
Group type: COMPARATOR
Intervention: Autonomy-controlling practice conditions
Number of subjects: 40
Study 29128736 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing choice (1-2-3-4) sequence
Number of subjects: 40
Study 29128736 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall motivation on the IMI
Number of subjects: 40
Study 29128736 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to the task on the UES Average Focused Attention subscale
Number of subjects: 40
Study 25832687 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with GCP (3 cycles of gemcitabine 1000 mg/m², carboplatin AUC 2.5, and paclitaxel 70 mg/m²) followed by concurrent chemo-radiation (radiation therapy 69.96 Gy with weekly cisplatin 40 mg/m²)
Number of subjects: 172
Study 25832687 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemo-radiation alone (control)
Number of subjects: 172
Study 25832687 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with GCP
Number of subjects: 172
Study 23829029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylindrical handhold diameter of 3.81 cm
Number of subjects: 397
Study 23829029 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical handhold diameters (various sizes)
Number of subjects: 397
Study 23829029 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength, age, and hand breadth as covariates
Number of subjects: 397
Study 21505224 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency care practitioners (ECPs)
Number of subjects: 1163
Study 19654536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir administered during the first 6 months after penetrating keratoplasty
Number of subjects: 47
Study 19654536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16731723 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐day healthy longevity lifestyle program combining a brain healthy diet plan, relaxation exercises, cardiovascular conditioning, and mental exercise (brain teasers and verbal memory training techniques)
Number of subjects: 17
Study 16731723 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle routine
Number of subjects: 17
Study 15536141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefazolin and ceftazidime (15 mg/kg rounded to nearest 100 mg)
Number of subjects: 13
Study 15536141 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (Phase I)
Number of subjects: 13
Study 10823386 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamines (epinephrine, norepinephrine, isoproterenol, and dopamine)
Number of subjects: 0
Study 10823386 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors
Number of subjects: 0
Study 10823386 — intervention group
Group type: COMPARATOR
Intervention: Supranormal oxygen delivery
Number of subjects: 0
Study 9071292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram-guided group
Number of subjects: 39
Study 9071292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 8261298 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sphere plug
Number of subjects: 40
Study 8261298 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sphere plug
Number of subjects: 40
Study 8261298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both plugs
Number of subjects: 40
Study 8261298 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral plug treatment
Number of subjects: 40
Study 3899047 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOIs) - clorgyline or tranylcypromine sulfate
Number of subjects: 14
Study 3899047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate
Number of subjects: 14
Study 3899047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during washout period)
Number of subjects: 14
Study 29985095 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 62
Study 29985095 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 62
Study 26122803 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 154
Study 26122803 — intervention group
Group type: COMPARATOR
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 154
Study 24298907 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen (clarithromycin, ethambutol, and rifampicin)
Number of subjects: 119
Study 24298907 — intervention group
Group type: COMPARATOR
Intervention: Two-drug regimen (clarithromycin and ethambutol)
Number of subjects: 119
Study 22116196 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100‐300 mg/day)
Number of subjects: 40
Study 22116196 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 40
Study 22116196 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 40
Study 18930189 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM/EE 25 microg
Number of subjects: 0
Study 18930189 — intervention group
Group type: COMPARATOR
Intervention: NETA/EE 20 microg
Number of subjects: 0
Study 17440125 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional weekly sessions
Number of subjects: 91
Study 17440125 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-therapist-contact sessions
Number of subjects: 91
Study 17440125 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 91
Study 16138585 — intervention group
Group type: EXPERIMENTAL
Intervention: Huorongbushen 48 g daily for 3 months
Number of subjects: 86
Study 16138585 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg daily for 3 months
Number of subjects: 86
Study 12503835 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (4 mg)
Number of subjects: 16
Study 12503835 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine (10 mg)
Number of subjects: 16
Study 12503835 — intervention group
Group type: EXPERIMENTAL
Intervention: thioridazine (50 mg)
Number of subjects: 16
Study 12503835 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 9796042 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular five‐component vaccine
Number of subjects: 0
Study 9796042 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular two‐component vaccine
Number of subjects: 0
Study 9796042 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed US whole cell vaccine
Number of subjects: 0
Study 9796042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9796042 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent pertussis vaccines
Number of subjects: 0
Study 9796042 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-pertactin, anti-fimbriae 2/3, and anti-PT
Number of subjects: 0
Study 7653464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 0
Study 1671890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nystatin
Number of subjects: 24
Study 1671890 — intervention group
Group type: COMPARATOR
Intervention: No treatment (antibacterial agents withdrawn)
Number of subjects: 24
Study 1671890 — intervention group
Group type: COMPARATOR
Intervention: Continuation of antibacterial therapy (without candida overgrowth)
Number of subjects: 24
Study 6186329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol followed by oral atenolol (5 mg IV, then 50 mg oral, 50 mg oral 12 hours later, then 100 mg daily for 10 days)
Number of subjects: 182
Study 6186329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol
Number of subjects: 182
Study 6186329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atenolol)
Number of subjects: 182
Study 31565794 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback during CPR training
Number of subjects: 115
Study 31565794 — intervention group
Group type: COMPARATOR
Intervention: No real-time feedback during CPR training (Control)
Number of subjects: 115
Study 30353790 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Well intervention
Number of subjects: 242
Study 30353790 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 242
Study 30353790 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency room use
Number of subjects: 242
Study 30463527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 0
Study 30463527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30463527 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 0
Study 26885786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 26885786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26885786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Problems Index I
Number of subjects: 0
Study 24679882 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy (Group 1)
Number of subjects: 60
Study 24679882 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery (Group 2)
Number of subjects: 60
Study 22154461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing syndrome treatment (surgical cure)
Number of subjects: 30
Study 22154461 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and body mass index-matched)
Number of subjects: 30
Study 19744828 — intervention group
Group type: COMPARATOR
Intervention: DiaPep277 (immune intervention)
Number of subjects: 99
Study 18763197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 20
Study 18763197 — intervention group
Group type: COMPARATOR
Intervention: Control group (classic treatment)
Number of subjects: 20
Study 16182105 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam, 5 mg (n = 17, study group)
Number of subjects: 36
Study 16182105 — intervention group
Group type: COMPARATOR
Intervention: Sublingual captopril, 25 mg (n = 19, control group)
Number of subjects: 36
Study 12597676 — intervention group
Group type: EXPERIMENTAL
Intervention: Patented chamomile preparation
Number of subjects: 0
Study 12597676 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study 10092302 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg urease + 5 microg heat-labile enterotoxin (LT)
Number of subjects: 26
Study 10092302 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg urease + 5 microg heat-labile enterotoxin (LT)
Number of subjects: 26
Study 10092302 — intervention group
Group type: COMPARATOR
Intervention: Placebo + LT
Number of subjects: 26
Study 10092302 — intervention group
Group type: EXPERIMENTAL
Intervention: Urease (any dose)
Number of subjects: 26
Study 10092302 — intervention group
Group type: EXPERIMENTAL
Intervention: Urease immunization
Number of subjects: 26
Study 10092302 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26
Study 7517172 — intervention group
Group type: EXPERIMENTAL
Intervention: LNH-84 or LNH-87 regimen
Number of subjects: 48
Study 2538050 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 or 15 g of soy polysaccharide fiber
Number of subjects: 0
Study 2538050 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of soy polysaccharide fiber
Number of subjects: 0
Study 2538050 — intervention group
Group type: COMPARATOR
Intervention: Fiber-free meal
Number of subjects: 0
Study 140827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofranil (25 mg three times a day for four weeks)
Number of subjects: 59
Study 140827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 140827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofranil
Number of subjects: 59
Study 30536191 — intervention group
Group type: EXPERIMENTAL
Intervention: Patented perfusion and suctioning platform and ureteral access sheath
Number of subjects: 122
Study 30536191 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study 28585859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with victim drugs
Number of subjects: 370
Study 28585859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with levothyroxine
Number of subjects: 370
Study 28585859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with metformin
Number of subjects: 370
Study 28585859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with ciprofloxacin
Number of subjects: 370
Study 28585859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with various drugs
Number of subjects: 370
Study 28585859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g administered 3 hours after victim drugs
Number of subjects: 370
Study 28585859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 25.2 g coadministered with ciprofloxacin, levothyroxine, and metformin
Number of subjects: 370
Study 25749297 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg once daily for 3 months
Number of subjects: 54
Study 25749297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23807837 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal microemulsion (formulation A)
Number of subjects: 32
Study 23807837 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil alone (formulation B)
Number of subjects: 32
Study 23807837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (formulation C)
Number of subjects: 32
Study 20193777 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored interactive stroke preparedness strategy
Number of subjects: 736
Study 20193777 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 736
Study 17643339 — intervention group
Group type: EXPERIMENTAL
Intervention: Push up on Swiss ball
Number of subjects: 10
Study 17643339 — intervention group
Group type: COMPARATOR
Intervention: Push up on Bench
Number of subjects: 10
Study 17643339 — intervention group
Group type: EXPERIMENTAL
Intervention: Push up plus on Swiss ball
Number of subjects: 10
Study 17643339 — intervention group
Group type: COMPARATOR
Intervention: Push up plus on Bench
Number of subjects: 10
Study 16339791 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed lidocaine (40 degrees C) 1% intra-articularly 20 min before surgery
Number of subjects: 2
Study 16339791 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature lidocaine (25 degrees C) 1% intra-articularly 20 min before surgery
Number of subjects: 2
Study 16339791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 12584283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (initial dose: 2.4 g/day, increased to 4.4 g/day)
Number of subjects: 42
Study 12584283 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (4.8 g/day)
Number of subjects: 42
Study 11357004 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.1 IU/kg
Number of subjects: 78
Study 11357004 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.2 IU/kg
Number of subjects: 78
Study 11357004 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 0.3 IU/kg
Number of subjects: 78
Study 11357004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GH treatment (0.3 IU/kg) interrupted
Number of subjects: 78
Study 8635106 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk counseling intervention
Number of subjects: 987
Study 1589558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.9 g/kg body weight
Number of subjects: 12
Study 1589558 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 1589558 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 12
Study 1589558 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg
Number of subjects: 12
Study 1589558 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 12
Study 1589558 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg and Diazepam 20 mg
Number of subjects: 12
Study 1589558 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam treatments
Number of subjects: 12
Study 3898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (0.5-2.5 g/day)
Number of subjects: 15
Study 3898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (0.5-1.5 g/day)
Number of subjects: 15
Study 3898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metyrapone and aminoglutethimide
Number of subjects: 15
Study 3898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone
Number of subjects: 15
Study 3898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 15
Study 31664452 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL) intervention
Number of subjects: 446